AXQ Capital LP Buys Shares of 26,002 Tempus AI, Inc. $TEM

Key Points

• AXQ Capital LP disclosed a new fourth-quarter stake in Tempus AI, buying 26,002 shares valued at about $1.535 million. Several other institutional investors also added to or initiated positions in the company.
• Analyst sentiment is mixed but still generally positive, with a Moderate Buy consensus and an average price target of $68.64. Recent notes included price-target changes from TD Cowen and JPMorgan, while others like Mizuho and Baird maintained bullish ratings.
• Tempus AI reported better-than-expected quarterly results, including 36.1% revenue growth year over year, and the stock was trading up 4.6% in the report. However, insiders have also been selling shares recently, including CEO Ryan Fukushima and EVP Andrew Polovin.

AXQ Capital LP bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 26,002 shares of the company's stock, valued at approximately $1,535,000.

Several other large investors also recently added to or reduced their stakes in the company. Lingotto Investment Management LLP raised its stake in Tempus AI by 45.9% during the 4th quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company's stock valued at $67,525,000 after purchasing an additional 359,667 shares during the period. Main Management ETF Advisors LLC increased its stake in shares of Tempus AI by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 26,622 shares of the company's stock worth $1,572,000 after acquiring an additional 272 shares during the last quarter. Nomura Asset Management Co. Ltd. acquired a new position in shares of Tempus AI in the fourth quarter worth $571,000. Norges Bank acquired a new position in shares of Tempus AI in the fourth quarter worth $48,234,000. Finally, Eurizon Capital SGR S.p.A. acquired a new position in shares of Tempus AI in the fourth quarter worth $70,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. TD Cowen upped their price target on shares of Tempus AI from $65.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 25th. Mizuho assumed coverage on shares of Tempus AI in a research note on Thursday, February 19th. They issued an "outperform" rating and a $100.00 price target on the stock. Robert W. Baird assumed coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They issued an "outperform" rating and a $59.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Tempus AI from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $68.64.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus announced the upcoming clinical availability of xH, its first whole-genome sequencing assay for hematologic malignancies, expanding its diagnostic menu and potentially opening a new revenue stream. Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
• Positive Sentiment: Tempus unveiled the next generation of Lens, its agentic AI platform for oncology drug development, which could strengthen its position with biopharma customers and support longer-term growth. Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
• Positive Sentiment: BTIG and Needham both reaffirmed buy ratings and assigned price targets well above the current share price, signaling continued analyst confidence. Analyst rating updates
• Positive Sentiment: Tempus also gained attention for new FDA-cleared companion diagnostic and AI oncology platform upgrades, adding to the bullish momentum around its product pipeline. Tempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform Upgrades
• Neutral Sentiment: A short-interest report showed Tempus AI’s short interest at a record high, which may increase volatility and suggests some investors remain skeptical. Short Report: Tempus AI short interest at record high

Tempus AI Trading Up 4.6%

Tempus AI stock opened at $52.80 on Tuesday. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The company has a market capitalization of $9.48 billion, a price-to-earnings ratio of -30.70 and a beta of 3.64. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32. The company's fifty day moving average price is $48.81 and its two-hundred day moving average price is $57.97.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. During the same period in the prior year, the business posted ($0.24) earnings per share. The business's quarterly revenue was up 36.1% on a year-over-year basis. On average, analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Ryan Fukushima sold 13,550 shares of the firm's stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $597,148.50. Following the sale, the chief executive officer owned 603,558 shares of the company's stock, valued at $26,598,801.06. This trade represents a 2.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 8,703 shares of the firm's stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $383,541.21. Following the completion of the sale, the executive vice president directly owned 128,215 shares in the company, valued at $5,650,435.05. This trade represents a 6.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 558,307 shares of company stock worth $26,599,589. Insiders own 24.26% of the company's stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.